Comparison between the inhibitory activities of SANGIVAMYCIN (cas 18417-89-5) and thioSANGIVAMYCIN (cas 18417-89-5) on nuclear ribonucleic acid synthesis in L1210 cells in vitro
-
Add time:09/05/2019 Source:sciencedirect.com
The molecular effects of the pyrrolopyrimidine analogs, SANGIVAMYCIN (cas 18417-89-5) and thiosangivamycin, on RNA and DNA synthesis were examined in L1210 cells in vitro. Pretreatment of cells for 30 min with either sangivamycin or thiosangivamycin resulted in a median inhibitory dose of 1 × 10−5 M and 2 × 10−5 M, respectively, for RNA synthesis. Sangivamycin did not inhibit DNA synthesis at comparable concentrations, while thiosangivamycin inhibited DNA synthesis by 20–35 per cent. Extending preincubation times with either drug to 1 hr resulted in decreased inhibition of RNA synthesis. Sangivamycin and thiosangivamycin also inhibited the transcription of nuclear RNA with 32P as precursor. Incorporation of 32P into AMP was reduced by both drugs to a much greater extent that the labeling of GMP, CMP, or UMP of alkaline hydrolysates of total nuclear RNA. Thiosangivamycin also significantly reduced methylation in nuclear rRNA. Neither drug affected the concentration or specific radioactivity of S-adenosyl-l-methionine or UTP. Sangivamycin and thiosangivamycin inhibited the syntheses of nuclear rRNA, non-poly(A) heterogeneous RNA and poly(A) heterogeneous RNA to equal extents, but the potency of sangivamycin was approximately 10-fold less than that of thiosangivamycin. These results suggest that sangivamycin and thiosangivamycin act as adenosine analogs to inhibit the transcription of all forms of nuclear RNA in L1210 cells.
We also recommend Trading Suppliers and Manufacturers of SANGIVAMYCIN (cas 18417-89-5). Pls Click Website Link as below: cas 18417-89-5 suppliers
Prev:Design, synthesis and activity against human cytomegalovirus of non-phosphorylatable analogs of toyocamycin, SANGIVAMYCIN (cas 18417-89-5) and thioSANGIVAMYCIN (cas 18417-89-5)☆
Next:Effect of SANGIVAMYCIN (cas 18417-89-5) and xylosyladenine on the synthesis and methylation of polysomal ribonucleic acid in Ehrlich ascites cells in vitro) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Antiviral activities of 2′-deoxyribofuranosyl and arabinofuranosyl analogs of SANGIVAMYCIN (cas 18417-89-5) against retro- and DNA viruses09/07/2019
- Effect of SANGIVAMYCIN (cas 18417-89-5) and xylosyladenine on the synthesis and methylation of polysomal ribonucleic acid in Ehrlich ascites cells in vitro09/06/2019
- Design, synthesis and activity against human cytomegalovirus of non-phosphorylatable analogs of toyocamycin, SANGIVAMYCIN (cas 18417-89-5) and thioSANGIVAMYCIN (cas 18417-89-5)☆09/04/2019
- In vivo and enzymatic conversion of toyocamycin to SANGIVAMYCIN (cas 18417-89-5) by Streptomyces rimosus☆09/03/2019
- X-ray crystal structure of SANGIVAMYCIN (cas 18417-89-5), a potent inhibitor of protein kinases09/02/2019
- Synthesis of 2′-β-C-methyl toyocamycin and SANGIVAMYCIN (cas 18417-89-5) analogues as potential HCV inhibitors09/01/2019
- ArticleDeciphering Deazapurine Biosynthesis: Pathway for Pyrrolopyrimidine Nucleosides Toyocamycin and SANGIVAMYCIN (cas 18417-89-5)08/31/2019
- SANGIVAMYCIN (cas 18417-89-5) induces apoptosis by suppressing Erk signaling in primary effusion lymphoma cells08/30/2019


